Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

NCT03876106 is registered in ClinicalTrials.gov with Lutris Pharma Ltd. as lead sponsor.

NCT NCT03876106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03876106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
Lead sponsor
Lutris Pharma Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2019
Completion date
November 18, 2020
Enrollment
10 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

egfr inhibitor induced acneiform lesions